AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 59 filers reported holding AUTOLUS THERAPEUTICS PLC in Q3 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $354,024 | -7.2% | 151,942 | -5.2% | 0.00% | – |
| Q2 2023 | $381,547 | +267.7% | 160,314 | +184.3% | 0.00% | – |
| Q1 2023 | $103,770 | -42.7% | 56,397 | -40.8% | 0.00% | – |
| Q4 2022 | $180,998 | +92.6% | 95,262 | +116.8% | 0.00% | – |
| Q3 2022 | $94,000 | -51.5% | 43,950 | -35.7% | 0.00% | – |
| Q2 2022 | $194,000 | -73.5% | 68,383 | -61.0% | 0.00% | – |
| Q1 2022 | $731,000 | -9.6% | 175,259 | +12.4% | 0.00% | – |
| Q4 2021 | $809,000 | -36.0% | 155,940 | -19.2% | 0.00% | – |
| Q3 2021 | $1,264,000 | -31.6% | 193,045 | -30.6% | 0.00% | – |
| Q2 2021 | $1,848,000 | +128.1% | 278,264 | +97.0% | 0.00% | – |
| Q1 2021 | $810,000 | -29.9% | 141,226 | +9.3% | 0.00% | – |
| Q4 2020 | $1,155,000 | +178.3% | 129,209 | +262.0% | 0.00% | – |
| Q3 2020 | $415,000 | -71.4% | 35,690 | -60.6% | 0.00% | – |
| Q2 2020 | $1,452,000 | +145100.0% | 90,578 | +335374.1% | 0.00% | – |
| Q1 2019 | $1,000 | – | 27 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 21,346,829 | $49,738,112 | 74.10% |
| TFG Asset Management GP Ltd | 12,000,000 | $27,960,000 | 5.10% |
| Paradigm Biocapital Advisors LP | 14,406,782 | $33,567,802 | 2.28% |
| Lynx1 Capital Management LP | 1,363,025 | $3,175,848 | 2.10% |
| Deep Track Capital, LP | 15,000,000 | $34,950,000 | 1.35% |
| Affinity Asset Advisors, LLC | 1,992,466 | $4,642,446 | 1.31% |
| DAFNA Capital Management LLC | 928,253 | $2,162,829 | 0.67% |
| Frazier Life Sciences Management, L.P. | 3,746,857 | $8,730,177 | 0.58% |
| ARMISTICE CAPITAL, LLC | 6,900,000 | $16,077,000 | 0.25% |
| Blackstone Inc. | 20,485,611 | $47,731,474 | 0.20% |